Who we are and what we do

We are a team of professionals with long time experience of in-vivo pharmacology and toxicology. We assist pharmaceutical companies in their endeavours to find cures for diseases for which there are no effective treatments today and those who are working to improve the effectiveness of discovered drugs.

How we work

Together with the customer we develop a project plan. Depending on the challenge Adlego Biomedical either runs projects solitary or puts together a group of experts from our network to manage complex projects. Therefore, we can be cost effective and produce with the highest quality a variety of studies from standard DMPK studies to demanding effect studies and large toxicity studies.

Why are preclinical studies needed?

To enter into clinical trials pharmaceutical companies need to demonstrate to regulatory agencies that a new drug is effective and relatively safe to administer to humans. Information about interactions between a new drug and a living organism is obtained with use of preclinical methods.


Our main focus is to establish long-term collaboration with drug developing companies that are early in their development of new candidate drugs. With this approach we establish a relationship that is fruitful for both parties when disease models need to be developed to show proof-of-concept, and when DMPK and toxicity data are gathered. Since we are working with experts within the various fields of drug development and document all studies according to GLP the customer is guaranteed top quality reports, which fulfil the requirements of regulatory bodies. 79334397-258x120


Although we have been working with many models of cancer we continue to get requests for models we have not used before. Before we use a new model in proof-of-concept studies we validate it to obtain information about growth rate and to show that the tumour is sensitive to current therapies. We commonly also use histological techniques to further analyze the effect of therapies. Here is an example from the validation of the ACHN tumour model: Bild31

Our Partners

Metasafe logo
PKXpert logo
meditox logo
Mercodia logo
Recipharm logo
Biovet logo
admescope logo
On Target Chemistry Link
Syntagon Logo

Latest News

Kanceras HDAC6-projekt tilldelas anslag från Vinnova

Pressmeddelande Stockholm 2015-06-12 Kanceras HDAC6-projekt tilldelas anslag från Vinnova Kancera har av Sveriges innovationsmyndighet VINNOVA tilldelats ett anslag om totalt 2,000,000 kronor riktat till projekt som kan utvecklas till nya starka innovationer. Delutbetalningar av anslaget sker vid fyra tillfällen under det två-åriga projektet. Anslaget kommer från det strategiska innovationsprogrammet för folksjukdomar (SWElife) vilket är ett nationellt initiativ för att stärka svensk life science och stödja nya innovationer inom en rad folksjukdomar, bland annat tumörsjukdomar. Kanceras HDAC6 projekt, med målet att utveckla en läkemedelskandidat mot cancer med en unik verkningsmekanism, har av Vinnova och externa experter bedömts vara ett projekt baserat på nyskapande och unika idéer och som kan utvecklas till en stark innovation inom cancerområdet. Projektet kommer att genomföras i samarbete med Cancer Centrum Karolinska (CCK) och planeras även involvera svenska företag som SARomics Biostructures, MetaSafe och Adlego Biomedical. Under december 2014 rapporterade Kancera att bolagets HDAC6-hämmare verkar genom ytterligare en unik mekanism som kan bidra till att hämma överlevnaden av cancerceller. Under 2015 har Kancera lämnat in en internationell patentansökan omfattande nya HDAC6 hämmare som i laboratoriestudier dödar såväl cancerceller som hjälparceller som återfinns i tumörer.   Om HDAC6-projektet Histone deacetylaser (HDACs) är primärt involverade i att ta bort acetyl-grupper från s.k. histoner som påverkar hur vår arvsmassa lagras och aktiveras i cellkärnan. Vissa HDACs påverkar också cellernas funktion utanför cellkärnan. HDAC6 tillhör denna grupp av HDACs och har sin stora biologiska roll som reglerare av cancercellens förmåga att röra sig och bilda metastaser. Användningen av HDAC-hämmare i behandlingen av cancerpatienter har hittills gett lovande resultat men begränsats av svåra biverkningar. Av denna anledning söker nu läkemedelsindustrin efter... read more

The true value of a good partnership!

  Urban Hoglund met Ari Tolonen, who is the CEO of Admescope, at the Nordic Life Science Day event in 2012. Admescope is a Finnish CRO that provides Bioanalytical services as part of their broad ADME-Tox service offering. The value of finding the right collaborative partner can take a long time to develop but they can also start to see business over night. Admescope was one of those companies that Adlego have been very happy to be working with. “It’s been great to work with a very active partner who wants to get the best service for their customer”, Urban said. Ari commented, “Adlego have been a good partner to work with, we feel their experience and care given to our projects makes them a great company to work with.”... read more


On Wednesday 22nd April in the afternoon, Adlego Biomedical were part of the Läkemedelseventet 2015. About 50 delegates were present who enjoyed listening to presentations about alternative and innovative solutions to advance the development of potential new medicines, methodologies when selling a pre-commercial life science company and experiences from establishment of successful life science companies. Urban Höglund said “It was interesting to see so many delegates from different companies. We got two potential leads that we hope will lead to work for us in the future, and we are looking forward to being part of the 2016... read more

Latest Publications

Mass spectrometry of macromolecules

Data on the use of accelerator mass spectrometry (AMS) in conjunction with in vivo studies of macromolecular drugs are scarce. The present study shows the versatility of this technique when investigating the pharmacokinetics (PK) of a macromolecular drug candidate, a polybisphosphonate conjugate (ODX). The aforementioned is a polymer (molecular weight ~30 kDa) constituting a carbohydrate backbone with covalently linked ligands (aldendronate and aminoguanidine) and is intended for treatment of osteoporosis and the therapy of bone metastasis from prostate cancer. The conjugate is prepared through partial oxidation of the carbohydrate and sequential coupling of the ligands by reductive amination. (14)C was incorporated in the conjugate by means of coupling a commercially available (14)C-lysine in the conjugation sequence. Fifteen rats were injected intravenously with (14)C-labelled ODX (150 µg, 14 Bq/rat) and blood samples were collected at 1, 2, 4, 6, and 24 h post-injection (3 rats/time point). Liver, spleen and kidney samples were collected at 4 and 24 h post-injection. Blood from each time point (triplicate) were collected for AMS measurement determining the isotopic ratio ((14)C/(12)C) and consequently the drug concentration in blood. ODX showed a transient presence in blood circulation; 93% of the total dose was cleared from the circulation within 1 h. The half-life after 1 h was estimated to be about 3 h; 0.7% of the administered (14)C dose of ODX remained in circulation after 24 h. The major (14)C accumulation was in the liver, the spleen and the kidneys indicating the probable route of metabolism and excretion. This study demonstrates the versatility of AMS for pharmacological in vivo studies of macromolecules. Labelling with (14)C is relatively simple, inexpensive and the method requires minimal radioactivity, eliminating the... read more

Multigene HIV vaccine

It is likely that gene-based vaccines will enter the human vaccine area soon. A few veterinary vaccines employing this concept have already been licensed, and a multitude of clinical trials against infectious diseases or different forms of cancer are ongoing. Highly important when developing novel vaccines are the safety aspects and also new adjuvants and delivery techniques needs to be carefully investigated so that they meet all short- and long-term safety requirements. One novel in vivo delivery method for plasmid vaccines is electroporation, which is the application of short pulses of electric current immediately after, and at the site of, an injection of a genetic vaccine. This method has been shown to significantly augment the transfection efficacy and the subsequent vaccine-specific immune responses. However, the dramatic increase in delivery efficacy offered by electroporation has raised concerns of potential increase in the risk of integration of plasmid DNA into the host genome. Here, we demonstrate the safety and lack of integration after immunization with a high dose of a multigene HIV-1 vaccine delivered intradermally using the needle free device Biojector 2000 together with electroporation using Derma Vax™ DNA Vaccine Skin Delivery System. We demonstrate that plasmids persist in the skin at the site of injection for at least four months after immunization. However, no association between plasmid DNA and genomic DNA could be detected as analyzed by qPCR following field inversion gel electrophoresis separating heavy and light DNA fractions. We will shortly initiate a phase I clinical trial in which healthy volunteers will be immunized with this multiplasmid HIV-1 vaccine using a combination of the delivery methods jet-injection and intradermal... read more

In vivo electroporation

The mechanisms by which in vivo electroporation (EP) improves the potency of i.m. DNA vaccination were characterized by using the hepatitis C virus nonstructural (NS) 3/4A gene. Following a standard i.m. injection of DNA with or without in vivo EP, plasmid levels peaked immediately at the site of injection and decreased by 4 logs the first week. In vivo EP did not promote plasmid persistence and, depending on the dose, the plasmid was cleared or almost cleared after 60 days. In vivo imaging and immunohistochemistry revealed that protein expression was restricted to the injection site despite the detection of significant levels of plasmid in adjacent muscle groups. In vivo EP increased and prolonged NS3/4A protein expression levels as well as an increased infiltration of CD3+ T cells at the injection site. These factors most likely additively contributed to the enhanced and broadened priming of NS3/4A-specific Abs, CD4+ T cells, CD8+ T cells, and gamma-IFN production. The primed CD8+ responses were functional in vivo, resulting in elimination of hepatitis C virus NS3/4A-expressing liver cells in transiently transgenic mice. Collectively, the enhanced protein expression and inflammation at the injection site following in vivo EP contributed to the priming of in vivo functional immune responses. These localized effects most likely help to insure that the strength and duration of the responses are maintained when the vaccine is tested in larger animals, including rabbits and humans. Thus, the combined effects mediated by in vivo EP serves as a potent adjuvant for the NS3/4A-based DNA vaccine. Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I,... read more